Instrument Inactif

Autres langues Covance Inc.

Actions

US2228161004

Cours en clôture Nyse Autres places de cotation
- ^USD	-

2014	Wall Street finit peu changée, pause des investisseurs	RE
2014	Dow Jones Industrial Average : Wall Street finit peu changée, pause des investisseurs	RE

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Covance : LabCorp Completes Acquisition of Covance	21/03/15
Covance : Launches New Solution to Bridge Preclinical to Clinical Development	20/01/15
Covance : Life Sciences Tools and Services Equities Coverage - Agilent Technologies, Thermo Fisher Scientific, Bruker, Quintiles Transnational, and Covance	08/12/14
Covance : Stockholders Encouraged to Contact Securities Law Firm about Takeover	04/11/14
Covance : Ryan & Maniskas, LLP : Announces Investigation of Covance Inc.	04/11/14
Covance : Dow, S&P 500 close slightly lower; semis boost Nasdaq	03/11/14
Covance : LabCorp to pay $6.1 billion for drug trial company Covance	03/11/14
Covance : LabCorp to pay $6.1 billion for drug trial company Covance	03/11/14
Covance : LabCorp to Acquire Covance for Approximately $5.6 Billion, Creating World’s Leading Healthcare Diagnostics Company	03/11/14
Covance : Technical Coverage on Life Sciences Tools and Services Equities - Agilent Technologies, Thermo Fisher Scientific, Pacific Biosciences of California, Sequenom, and Covance	27/10/14
Covance : Receives Frost & Sullivan Asia Pacific CRO Growth Excellence Leadership Award	17/10/14
Covance : Invites You to Join the Webcast of Its Third Quarter 2014 Financial Results Conference Call	08/10/14
Covance : and Frenova Renal Research Establish	18/09/14
Covance : To Present At The Morgan Stanley Global Healthcare Conference	07/09/14
Covance : Financial Results, Investor Meeting Schedule, Dividend Declaration, and Technical Updates - Research Reports on Quest, Abaxis, Charles River Laboratories, PerkinElmer and Covance	30/07/14
Covance : Invites You to Join the Webcast of Its Second Quarter 2014 Financial Results Conference Call	30/07/14
Covance : Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million	29/07/14
Covance : Increases its Medical and Scientific Leadership with Two Senior-Level Appointments	09/07/14
Covance : C O R R E C T I O N -- Covance Inc./	02/07/14
Covance : New Laws, Pricing of Offering, Recognitions, Donations, and Upcoming Conference Calls - Analyst Notes on Hospira, Prothena, Quintiles, Sirona and Covance	30/06/14

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Covance Inc.

Actions

US2228161004

Autres langues

Filtres